Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis
- PMID: 51344
- DOI: 10.1016/s0140-6736(75)90896-x
Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis
Abstract
The concentration of herpes-simplex virus (H.S.V.) in the lesions of adults with recurrent herpes labialis was determined. On the 1st day the vesicle appeared, the fluid within the lesion contained 10(5-3) plaque-forming units (P.F.U.) of H.S.V./mul. By swabbing the surface of the lesions with a sterile pledget, 10(6-2) P.F.U. of virus was isolated from the inflamed labial mucosa. The amount of virus obtained from the labial surface decreased on the 2nd and 3rd day to 10(5-0) and 10(3-0) P.F.U., respectively. In two patients on immunosuppressive drugs, high concentrations of virus (greater than 10(4-0) P.F.U.) were obtained per swab for more than 3 weeks. The presence of infectious virus-antibody (V.A.) complexes in herpetic lesions was demonstrated by examining fifty-two isolates from twenty-eight patients at various times during the course of their disease. 71% of the patients had V.A. complexes in their lesions on the 1st day of the vesicular eruption, and by the 3rd day all of the lesions examined contained complexes. It is concluded that patients with active lesions shed high concentrations of virus and that natural infection may be transmitted by an infectious V.A. complex.
Similar articles
-
Antibodies to herpes-simplex virus in "normal" cerebrospinal fluid.Lancet. 1976 Jan 10;1(7950):654-5. Lancet. 1976. PMID: 54583
-
The natural history of recurrent facial-oral infection with herpes simplex virus.J Infect Dis. 1978 Dec;138(6):897-905. doi: 10.1093/infdis/138.6.897. J Infect Dis. 1978. PMID: 216753
-
Immune inhibition of virus release from herpes simplex virus-infected cells by human sera.Intervirology. 1988;29(3):125-32. doi: 10.1159/000150038. Intervirology. 1988. PMID: 2846463
-
An update on short-course intermittent and prevention therapies for herpes labialis.Herpes. 2007 Jun;14 Suppl 1:13A-18A. Herpes. 2007. PMID: 17877887 Review.
-
The natural history of recurrent oral-facial herpes simplex virus infection.Semin Dermatol. 1992 Sep;11(3):200-6. Semin Dermatol. 1992. PMID: 1390034 Review.
Cited by
-
Comparison of fluorescent-antibody, neutralizing-antibody, and complement-enhanced neutralizing-antibody assays for detection of serum antibody to respiratory syncytial virus.J Clin Microbiol. 1981 May;13(5):957-62. doi: 10.1128/jcm.13.5.957-962.1981. J Clin Microbiol. 1981. PMID: 7016915 Free PMC article.
-
Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses.Infect Immun. 1976 Jun;13(6):1567-78. doi: 10.1128/iai.13.6.1567-1578.1976. Infect Immun. 1976. PMID: 1085748 Free PMC article.
-
Enhanced antiglobulin-mediated neutralization of herpes simplex virus-IgG complexes by complement and heterologous anti-immunoglobulin.Arch Virol. 1979;59(1-2):89-97. doi: 10.1007/BF01317898. Arch Virol. 1979. PMID: 218539
-
Persistent viral infections as models for research in virus chemotherapy.Adv Virus Res. 1981;26:37-64. doi: 10.1016/s0065-3527(08)60420-0. Adv Virus Res. 1981. PMID: 6164273 Free PMC article.
-
Application and tolerability of Herpotherm(®) in the treatment of genital herpes.Clin Cosmet Investig Dermatol. 2013 Jun 5;6:163-6. doi: 10.2147/CCID.S41145. Print 2013. Clin Cosmet Investig Dermatol. 2013. PMID: 23776340 Free PMC article.